New Developments in Depression, Anxiety, Compulsiveness, and Hallucinations in Parkinson's Disease

被引:24
作者
Goetz, Christopher G. [1 ,2 ]
机构
[1] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA
[2] Rush Univ, Med Ctr, Dept Pharmacol, Chicago, IL 60612 USA
关键词
Parkinson's disease; depression; anxiety; compulsiveness; psychiatric impairment; hallucinations; DEEP BRAIN-STIMULATION; NURSING-HOME PLACEMENT; VISUAL HALLUCINATIONS; DIAGNOSTIC-CRITERIA; IMPULSE CONTROL; RISK-FACTORS; REPETITIVE BEHAVIORS; MINOR DEPRESSION; DOPAMINE; PSYCHOSIS;
D O I
10.1002/mds.22636
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Increasing research efforts are focused on nonmotor aspects of Parkinson's disease (PD). Depression, anxiety, compulsivity (dopamine dysregulation symptoms), and hallucinations/psychosis are among these disorders, and all complicate the management of PD with negative influences on quality of life. There is a strong overlap between depression and apathy and likewise, depression and anxiety can coexist and require careful pharmacologic management. Dopamine dysregulation syndrome is linked to medication use and most clearly associated with dopamine agonists. In contrast, although hallucinations and psychosis do not occur unless patients with PD are treated with dopaminergic drugs, medication doses do not directly relate to this problem. Functional neuroimaging provides an excellent resource for investigating these behaviors as well as their anatomical and neurochemical bases. New treatments are being developed, but there have been very few large-scale randomized clinical trials to test the relative roles of new or available agents for abating these problematic behaviors. (C) 2010 Movement Disorder Society
引用
收藏
页码:S104 / S109
页数:6
相关论文
共 72 条
[1]   Predictors of nursing home placement in Parkinson's disease: A population-based, prospective study [J].
Aarsland, D ;
Larsen, JP ;
Tandberg, E ;
Laake, K .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2000, 48 (08) :938-942
[2]   Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission [J].
Alex, K. D. ;
Pehek, E. A. .
PHARMACOLOGY & THERAPEUTICS, 2007, 113 (02) :296-320
[3]  
American Psychiatric Association, 2013, Diagnostic and statistical manual of mental disorders, DOI 10.1176/appi.books.9780890425596
[4]  
[Anonymous], 2007, BASIC CLIN PHARM
[5]   Psychiatric and neuropsychiatric adverse events associated with deep brain stimulation: A meta-analysis of ten years' experience [J].
Appleby, Brian S. ;
Duggan, Patrick S. ;
Regenberg, Alan ;
Rabins, Peter V. .
MOVEMENT DISORDERS, 2007, 22 (12) :1722-1728
[6]   Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation [J].
Ardouin, Claire ;
Voon, Valerie ;
Worbe, Yulia ;
Abouazar, Nehman ;
Czernecki, Virginie ;
Hosseini, Hassan ;
Pelissolo, Antoine ;
Moro, Elena ;
Lhommee, Eugenie ;
Lang, Anthony E. ;
Agid, Yves ;
Benabid, Alim-Louis ;
Pollak, Pierre ;
Mallet, Luc ;
Krack, Paul .
MOVEMENT DISORDERS, 2006, 21 (11) :1941-1946
[7]  
Arnulf I, 2006, J NEURAL TRANSM-SUPP, P357
[8]   Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease [J].
Bandini, Fabio ;
Primavera, Alberto ;
Pizzorno, Matteo ;
Cocito, Leonardo .
PARKINSONISM & RELATED DISORDERS, 2007, 13 (06) :369-371
[9]  
BARONE P, 2007, MOV DISORD S16, V22, pS181
[10]   Pramipexole versus sertraline in the treatment of depression in Parkinson's disease - A national multicenter parallel-group randomized study [J].
Barone, Paolo ;
Scarzella, Leonardo ;
Marconi, Roberto ;
Antonini, Angelo ;
Morgante, Letterio ;
Bracco, Fulvio ;
Zappia, Mario ;
Musch, Bruno .
JOURNAL OF NEUROLOGY, 2006, 253 (05) :601-607